F1901 is an innate immune system enhancer having great potential for targeting different types of cancer, and is set to become a blockbuster in immunotherapy.

F1901 mechanism of action has been extensively studied at Gustave Roussy.

In immunocompetent murine models, F1901 has been shown to:

• Induce immunogenic tumor cell death and antitumor vaccination with a dose response effect

• Enhance response to anti-PD1

Because of their similar biology and response to treatment, canine solid tumors may serve as a translational model for human cancer.